- Tack Endovascular System®
- Clinical Trials
- Peripheral Artery Disease
- Contact Us
This animation is provided for general information only. It is not intended to provide clinical instructions for use (IFU). Always read and understand the IFU supplied with the device prior to use.
Intact Vascular is committed to developing safe, efficacious and easy-to-use products for patients with vascular disease and the physicians who treat them. Founded in 2011, our core technology, the Tack Endovascular System®, is a new option for dissection repair in lower extremities and an adjunct to peripheral balloon angioplasty. Intact Vascular is a privately held medical device company located in Wayne, PA.
Bruce Shook is a highly-experienced, medical device executive with more than 30 years of industry experience, including multiple early stage ventures focused on opportunities in cardiac surgery, cardiology, neurosurgery, psychiatry and vascular disease. Mr. Shook joined Intact Vascular as Director, President and CEO in 2014 and has been instrumental in the Company’s development of the Tack Endovascular System®, a new technology for the repair of diseased peripheral arteries. Prior to Intact Vascular, Mr. Shook was co-founder, Director, President and CEO of Neuronetics, Inc., which is a privately held medical device company that markets a non-invasive brain stimulation technology for the treatment of depression.
Previously, Mr. Shook was co-founder, Director, President and CEO at Neuron Therapeutics, a venture-backed company developing a drug/device product for the treatment of CNS disorders and President of Abiomed [NASDAQ: ABMD] where he successfully obtained PMA approval for the first, FDA-approved ventricular assist device. Mr. Shook also developed cardiac pacing and anti-arrhythmia products at Cordis Corporation.
Mr. Shook holds advanced degrees in Biomedical Engineering and Business Administration from Columbia University and the MIT Sloan School of Management, respectively. He earned a B.S. degree in Chemical Engineering from Penn State University. Mr. Shook currently serves on the Board of Directors at Venarum Medical, the Penn State Research Foundation and the Pennsylvania Biotechnology Association. He previously served as a Director at Surgiquest, Respicardia and CoTherix.
Dr. Peter Schneider is a world-renowned vascular surgeon, who currently practices at Kaiser Permanente Clinic in Honolulu, Hawaii. He is the Principal Investigator in a U.S. drug-coated balloon trial sponsored by Medtronic as well as the Principal Investigator in a carotid stent trial sponsored by WL Gore. Dr. Schneider licensed vascular devices to Cook Medical (tibial sheath) and developed a marker catheter for carotid interventions, which was licensed to Angiodynamics.
An early adopter of endovascular techniques, he has authored multiple scientific publications and books, including Endovascular Skills, Critical Limb Ischemia and Carotid Interventions. Dr. Schneider frequently speaks at national and international conferences. He serves on the scientific advisory boards of Abbott, Medtronic and Cordis. Dr. Schneider also serves as an advisor for Revascular, Silk Road and Pro-med.Dr. Schneider earned a B.A.-M.D. from Johns Hopkins University School of Medicine and completed his internship, residency and fellowship at the University of California San Diego.
Mr. Joseph C. Griffin, III has more than 35 years of experience in the design, development, regulatory compliance and manufacturing of numerous leading-edge, cardiovascular devices. He joined Intact Vascular in 2014 to establish a robust quality management system and direct domestic and international regulatory projects from submission preparation through approvals.
Previously, he served as Vice President of Regulatory Affairs and Compliance Officer at Flexible Stenting Solutions, a subsidiary of Cordis Corporation. In this role, he executed various regulatory, quality, clinical and compliance duties that led to the Cordis acquisition in 2013. Before, Mr. Griffin founded Professional Catheter Corporation, where he served as President until the EP MedSystems acquisition in 1993. Upon acquisition, he was appointed Vice President of Regulatory Affairs and played a key role in EP MedSystems IPO in 1995 (NASDAQ: EPMD). He also served as Director of Research and Development at Oscor Medical Corporation and Director of Research, Development and Technical Services at Nova Medical Specialties, leading to its acquisition by B. Braun of America in 1987.
Mr. Griffin attended several academic institutions and earned numerous certificates in Medical Plastics Technology, Silicone & Polyurethane for Medical Applications, Advanced Medical Plastics, ISO 13485 and Auditing. He is a published co-author in the area of medical device thrombogenicity research and an inventor/co-inventor, who holds 15 medical device-related U.S. patents.
Mr. Howard Rosen has more than 25 years of commercial experience in sales, upstream and downstream marketing, market development and business unit general management across multiple cardiovascular market segments. He joined Intact Vascular in 2017 and will lead the company’s efforts to prepare for commercialization of its Tack Endovascular System® for the repair of dissections following peripheral artery angioplasty.
Prior to joining Intact Vascular, Mr. Rosen’s career included twenty-one years at Boston Scientific Corporation, where he began his career as a sales representative and rose through the marketing ranks to hold positions of increasing responsibility in the peripheral vascular interventions and cardiovascular businesses. Mr. Rosen most recently served as Vice President of the Cell Processing Franchise at the Haemonetics Corporation.
Mr. Rosen holds a B.S. in Business Administration from Northeastern University.
With a background in Quality, Regulatory and Manufacturing, Mr. Mike Longo started in 2013 at Intact Vascular to manage the pipeline of innovative product development and oversee R&D activities. He has extensive medical device engineering experience that includes a strong knowledge of Quality Systems Regulations, ISO 9001 and 13485 as well as management experience for Class I, II and III development programs for cardiovascular and diabetes care products.
Previously, Mr. Longo served as a Staff Design Quality Engineer at Animas Corporation, a Johnson & Johnson Company. Before then, he was an Engineering Manager at Bioconnect Systems with responsibilities for developing an arteriovenous fistula implant and reusable delivery instruments. Mr. Longo also worked at Kensey Nash (now DSM) in senior-level product development and manufacturing engineering roles.
Mr. Longo earned a B.S. degree in Electro-Mechanical Engineering from Pennsylvania State University.
With more than 10 years of experience managing all phases of clinical research for medical devices, Mr. Marc Penna started in 2015 and is responsible for creating short-and long-term clinical plans with a focus on trial enrollment. He has held both executive and clinical data/clinical trial program management roles within the cardiovascular, endovascular and oncology therapeutic areas.
Recently, he served as the Senior Director of Clinical and Medical Affairs at AngioDynamics, where he was responsible for all worldwide clinical activity. Earlier in his career, Mr. Penna worked on the transcatheter aortic valve replacement (TAVR) pivotal trials at Edwards Life Sciences as well as on the drug eluting stent program at Boston Scientific.Mr. Penna holds a B.S. in Management Information Systems from Central Connecticut State University.
Having joined Intact Vascular in 2014, Ms. Monica Klos is responsible for coordinating company planning, forecasting and budgeting, financial reporting and all accounting operations. She has more than 20 years of accounting and financial experience, primarily in the life science industry.
Formerly, she was the Controller for NuPathe, where she was responsible for SEC financial reporting, compliance, accounting and budget oversight, equity compensation. Ms. Klos had previously served as the Controller for Neose Technologies. She began her career with KPMG before holding positions of increasing responsibility at various life science companies.
Ms. Klos received a B.S. degree in Accounting from Villanova University and is a Certified Public Accountant in Pennsylvania.
George L. Adams, MD
Heart & Vascular Surgery
REX UNC Health Care
Marianne Brodmann, MD
Professor of Internal Medicine
Division of Angiology
Medical University Graz
Michael D. Dake, MD
Professor, Cardiothoracic Surgery-
Adult Cardiac Surgery
Stanford University School of Medicine
David H. Deaton, MD, FACS
Vascular Surgeon, Cleveland Clinic Ohio
Chief Medical Officer, Endologix, Inc.
William A. Gray, MD
System Chief of Cardiovascular Services,
Main Line Health; President, Lankenau Heart Institute
Patrick J. Geraghty, MD
Professor, Surgery and Radiology
Washington University in St. Louis
John R. Laird, MD
Medical Director, Professor of Medicine
UC Davis Cardiovascular Medical Center
Alan B. Lumsden, MD, ChB, RVT, FACS
Chair, Department of Cardiovascular Surgery
Methodist DeBakey Heart and Vascular Center
Professor of Cardiothoracic Surgery
Weill Cornell Medical College of Cornell University
Jihad A. Mustapha, MD, FACC, FSCAI
Director Cardiovascular Catheterization Laboratories, Endovascular Interventions and Cardiovascular Research
Metro Health Hospital, Wyoming, MI
Clinical Assistant Professor of Medicine Michigan State University CHM and COM, East Lansing, MI
Founder and Director of the AMPutation Prevention Symposium
Rodney A. White, MD
Vascular Surgery Division Chief
Harbor-UCLA Medical Center
a world that is free from the pain and disability that is associated with peripheral vascular disease.
We are dedicated to improving life for patients suffering from peripheral artery disease.
PATIENTS COME FIRST
RESPECT FOR PEOPLE